Leucocytes Identified by Automated Digital Morphology System
|
By LabMedica International staff writers Posted on 31 Oct 2013 |

Image: CellaVision DM96 Digital Cell Morphology System (Photo courtesy of CellaVision).
An automated digital cell morphology analyzer for determining leukocyte differential counts in peripheral blood smears (PBS) has been evaluated in a clinical laboratory.
The differential counting of peripheral blood leukocytes is one of the most frequently ordered laboratory tests by clinicians as it is an important test for the diagnosis of various hematologic diseases and systemic diseases. Improvements in laboratory technologies have benefited from the development of automated blood cell counters that have begun to replace the manual microscopic counting that is still performed in most laboratories.
Laboratory scientists at the University of Ulsan College of Medicine and Asan Medical Center (Seoul, Republic of Korea) examined a total of 308 peripheral blood samples with quantitative or qualitative abnormalities, for which complete blood counts had been ordered by clinicians. These samples were initially analyzed using the automatic blood cell analyzer Sysmex XE-2100 (Sysmex; Kobe, Japan), and the total leukocyte and differential counts were determined. Manual microscopic differential counts of 100 cells on each slide were separately performed by two independent well-trained laboratory technologists.
The slides were labeled and loaded into the CellaVision DM96 system (CellaVision AB; Lund, Sweden) after manual microscopic differential counting. In cases with a buffy coat preparation, the slides were prepared using samples prior to buffy coat preparation and labeled in the CellaVision DM96 system To evaluate the clinical relevance of the extension of cell counts up to 300 or 500 cells, which is the provided function by the CellaVision DM96 system, in the samples with low leukocyte count of less than 1,000 cells/μL, correlation analysis between the CellaVision DM96 system and manual count was performed.
The correlation coefficients between two methods were consistently high, ranged from 0.864 to 0.992. The sensitivity, specificity, positive predictive value, negative predictive values of this system for the identification of abnormalities was consistently high, especially for blast cells. When the instrument was instructed to count 300 or 500 cells from the operator, better performance was demonstrated than 100 cells in the leukopenic samples by sacrificing only 40 seconds/slide on average.
The authors concluded that the CellaVision DM96 system is useful in the clinical laboratory providing comparative accuracy compared with manual counts in samples with abnormalities. In leukopenic samples, report quality can be improved by ordering to count 300 or 500 cells from the operator without severe prolongation of turnaround time. The study was published on the October 2013 issue of the International Journal of Laboratory Hematology .
Related Links:
University of Ulsan College of Medicine and Asan Medical Center
Sysmex
CellaVision AB
The differential counting of peripheral blood leukocytes is one of the most frequently ordered laboratory tests by clinicians as it is an important test for the diagnosis of various hematologic diseases and systemic diseases. Improvements in laboratory technologies have benefited from the development of automated blood cell counters that have begun to replace the manual microscopic counting that is still performed in most laboratories.
Laboratory scientists at the University of Ulsan College of Medicine and Asan Medical Center (Seoul, Republic of Korea) examined a total of 308 peripheral blood samples with quantitative or qualitative abnormalities, for which complete blood counts had been ordered by clinicians. These samples were initially analyzed using the automatic blood cell analyzer Sysmex XE-2100 (Sysmex; Kobe, Japan), and the total leukocyte and differential counts were determined. Manual microscopic differential counts of 100 cells on each slide were separately performed by two independent well-trained laboratory technologists.
The slides were labeled and loaded into the CellaVision DM96 system (CellaVision AB; Lund, Sweden) after manual microscopic differential counting. In cases with a buffy coat preparation, the slides were prepared using samples prior to buffy coat preparation and labeled in the CellaVision DM96 system To evaluate the clinical relevance of the extension of cell counts up to 300 or 500 cells, which is the provided function by the CellaVision DM96 system, in the samples with low leukocyte count of less than 1,000 cells/μL, correlation analysis between the CellaVision DM96 system and manual count was performed.
The correlation coefficients between two methods were consistently high, ranged from 0.864 to 0.992. The sensitivity, specificity, positive predictive value, negative predictive values of this system for the identification of abnormalities was consistently high, especially for blast cells. When the instrument was instructed to count 300 or 500 cells from the operator, better performance was demonstrated than 100 cells in the leukopenic samples by sacrificing only 40 seconds/slide on average.
The authors concluded that the CellaVision DM96 system is useful in the clinical laboratory providing comparative accuracy compared with manual counts in samples with abnormalities. In leukopenic samples, report quality can be improved by ordering to count 300 or 500 cells from the operator without severe prolongation of turnaround time. The study was published on the October 2013 issue of the International Journal of Laboratory Hematology .
Related Links:
University of Ulsan College of Medicine and Asan Medical Center
Sysmex
CellaVision AB
Latest Hematology News
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Channels
Clinical Chemistry
view channel
International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more
Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
Prostate cancer is among the most common cancers in men, and the role of population screening has remained controversial because of overdiagnosis and overtreatment. Health systems have sought clearer,... Read moreMolecular Diagnostics
view channel
Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read more
New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy
Peripheral neuropathy is a common neurological disorder that causes pain, sensory loss, imbalance, and weakness, affecting an estimated 12%–20% of people in the U.S. and nearly 30% of adults over age 65.... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read more
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read moreIndustry
view channel
Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
Selecting treatments for advanced cancer remains difficult when bulk analyses mask the functional diversity of tumor cells and mechanisms of resistance that emerge over time. Clinicians increasingly need... Read more








